Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: <https://www.ijmmttd.org/>

Case Series

Chromobacterium violaceum: A report of two cases of septicaemia and wound infection

Iqra Anjum^{1,*}, Maimoona Mustafa¹, Mohammed Khaleel¹¹Dept. of Microbiology, Deccan College of Medical Sciences, Hyderabad, Telangana, India

ARTICLE INFO

Article history:

Received 25-02-2021

Accepted 09-03-2021

Available online 26-03-2021

Keywords:

Chromobacterium violaceum

Septicaemia

wound infection

ABSTRACT

Background: Chromobacterium violaceum is a rare cause of human infection, which may become life threatening to its' ability to rapidly disseminate. Cases are few and far between but with the climate change can increase in number. Here we discuss two (2) cases of infection with C. violaceum isolated at our hospital in South India.

Materials and Methods: Samples collected with all aseptic precautions were subjected for aerobic culture and the isolates subjected to various biochemical tests for identification.

Result: Infection by C. violaceum was confirmed in both the cases and appropriate antimicrobial administered.

Conclusion: Timely treatment with appropriate antimicrobial agents can reduce morbidity and prevent mortality by halting the progression of a local infection to systemic disease.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Chromobacterium violaceum is a gram-negative, oxidase positive, motile bacillus. It's a natural inhabitant of soil and aquatic bodies of tropic and subtropical regions.

C. violaceum was first discovered in 1881¹ but human pathogenicity was discovered in 1927 after the first human case was reported from Malaysia.²

Human pathogenicity is rare with only >150 cases reported from around the world.³ The last case from India was reported in 2017 by Tiwari et al.⁴ Usually bloodstream infection is preceded by skin infection. C. violaceum septicaemia is highly fatal if not treated promptly. Relapses following therapy are also fairly common.⁵

2. Case 1

A 50 year old female patient was brought to the emergency department with signs of right hemiparesis. On examination patient was drowsy, irritable, not responding to verbal

commands.

She was febrile on admission with Pulse Rate of 105 bpm and Blood Pressure measuring 170/100 mmHg and SPO₂ concentration at 97%. She was a known hypertensive, non-diabetic, non-smoker, non-alcoholic.

CT-Brain revealed Left Intracranial Haemorrhage with midline shift.

On further examination it was observed that the patient had multiple papulopustular lesions on her back.

3. Materials and Methods

With the ethical clearance obtained from our Institutional Review Board and Ethics Committee, the patient was subjected to complete examination.

3.1. Blood culture

10 ml of blood was collected aseptically via fresh venepuncture and inoculated into BACTEC blood culture bottle and incubated at 37°C, aerobically for 24 hours following which subcultures were made onto Nutrient,

* Corresponding author.

E-mail address: dr.igraiftaquir@gmail.com (I. Anjum).

MacConkey and Blood Agar and further incubated at 37°C under aerobic conditions for 18 hours. After this, the following colony morphology was observed:

3.1.1. Nutrient agar

Smooth circular colonies with regular margins and a deep violet coloured non-diffusible pigment.

3.1.2. MacConkey agar

Violet coloured Non-Lactose Fermenting Colonies.

3.1.3. Blood agar

Non-Haemolytic colonies.

Gram stained smears from both blood culture bottle and isolated colonies from culture plates showed similar morphology of gram negative bacilli. These were motile, catalase and oxidase positive. Thus the isolate was presumptively identified as *Chromobacterium violaceum* based on these findings and the characteristic pigment.

This isolate was re-isolated by repeated blood culture which ruled out the possibility of it being a contaminant. The isolate was then subjected to various biochemical tests, as shown in Table 1.

Antimicrobial susceptibility testing was carried out via Kirby-Bauer disk diffusion method on Muller Hinton Agar. As CLSI guidelines for *C. violaceum* are not established owing to its rare implication in human infection, the results were interpreted according to the CLSI 2020 guidelines for non-fermenters, shown here in Table 2.

3.2. Case 2

A 37 year old male patient came to surgical department with history of fall from bike after which the wound was cleaned and dressed at a local clinic. The patient was non-diabetic, non-hypertensive. On Day 3 he developed pus for which he came to our hospital. Wound swab was collected and subjected to microscopy and culture. Direct Gram's stain showed Gram-negative bacilli.

4. Materials and Methods

With the ethical clearance obtained from our Institutional Review Board and Ethics Committee, the patient was subjected to complete examination.

4.1. Culture From Wound SWAB

On inoculation onto Nutrient, MacConkey and Blood agar the following colony morphology was observed:

4.1.1. Nutrient agar

Smooth circular colonies with regular margins and a deep violet coloured non-diffusible pigment.

4.1.2. MacConkey agar

Violet coloured Non-Lactose Fermenting Colonies

4.1.3. Blood agar

Non-Haemolytic colonies.

Gram's staining, motility and biochemical reactions lead identification of the isolate as *Chromobacterium violaceum*. The antimicrobial susceptibility pattern was observed as tabulated in Table 4.

The patient recovered without any complications after administration of antibiotics.

Table 1: Biochemical properties of *Chromobacterium violaceum* isolate.

Biochemical Tests	Result
Indole	Negative
TSI	K/A, NO GAS, NO H ₂ S
Citrate	Positive
Urease	Positive
Nitrate reduction	Positive
Voges-prauskuer	Negative
Methyl-red	Negative
Esculin hydrolysis	Negative
Arginine dihydrolase	Positive
Carbohydrate utilisation test	
• Glucose	Fermented, No Gas
• Lactose	Not fermented
• Sucrose	Not fermented
• Maltose	Fermented
• Mannitol	Not fermented

Table 2: Antimicrobial Susceptibility Pattern of the Isolate

Antimicrobial Agent	Zone Size	Interpretation
Ciprofloxacin (30µg)	27MM	Sensitive
Chloramphenicol (30µg)	30MM	Sensitive
Piperacillin-Tazobactam (100/10µg)	22MM	Sensitive
Trimethoprim-Sulfamethoxazole (1.25µg/23.75µg)	20MM	Sensitive
Doxycycline (30µg)	17MM	Sensitive
Meropenem (10µg)	17MM	Intermediate Sens.
Levofloxacin (5µg)	15MM	Intermediate Sens.
Ampicillin (10µg)	11MM	Resistant
Gentamicin (10µg)	10MM	Resistant
Amikacin (30µg)	10MM	Resistant
Cephazolin (30µg)	16MM	Resistant
Ceftriaxone (30µg)	17mm	Resistant

Table 3: Heamatological and Biochemical Parameters

Investigation	Result	Reference Value
Haemoglobin	13.3gm/dl	11-15gm/dl
WBC	11,400/cu. mm.	4,000-11,000/cu. mm.
	With Relative Neutrophilia	
Platelets	2,80,000/cu.mm.	1,50,000-4,00,000/cu. mm.
Procalcitonin	6.40 μ g/L	<0.5 μ g/L
Serum alkaline phosphatase	154U/L	30-120U/L
G6PD Level	8U/gm Hb	6.75-11.95U/gm Hb

Fig. 1: Papulopustular Lesions over the Back Seen in Case 1.**Table 4:** Antimicrobial Susceptibility Pattern of the Isolate

Antimicrobial agent	Zone size	Interpretation
Ciprofloxacin (30 μ g)	27mm	Sensitive
Chloramphenicol (30 μ g)	30mm	Sensitive
Piperacillin-tazobactam (100/10 μ g)	22mm	Sensitive
Trimethoprim-Sulfamethoxazole (1.25 μ g/23.75 μ g)	20mm	Sensitive
Doxycycline (30 μ g)	17mm	Sensitive
Meropenem (10 μ g)	17mm	Sensitive
Gentamicin (10 μ g)	18mm	Sensitive
Levofloxacin (5 μ g)	15mm	Intermediate sens.
Ampicillin (10 μ g)	11mm	Resistant
Amikacin (30 μ g)	10mm	Resistant
Cephazolin (30 μ g)	16mm	Resistant
Ceftriaxone (30 μ)	17mm	Resistant

Fig. 2: Gram stain from culture showing Gram-Negative Bacilli**Table 5:** Heamatological and Biochemical Parameters

Investigation	Result	Reference Value
Haemoglobin	12.1gm/dl	11-15gm/dl
WBC	6,500/cu. mm.	4,000-11,000/cu. mm.
Platelets	3,20,000/cu.mm.	1,50,000-4,00,000/cu. mm.
Procalcitonin	0.40 μ g/L	<0.5 μ g/L
Serum alkaline phosphatase	54U/L	30-120U/L
G6PD Level	6.8U/gm Hb	6.75-11.95U/gm Hb

Fig. 3: Colony morphology of *C. violaceum* on Nutrient, MacConkey and Blood Agar

Fig. 4: Wound Swab Being Collected From Site of Injury in Case 2

5. Discussion

Chromobacterium violaceum is a facultative anaerobic Gram-negative bacilli, ubiquitously present in soil and water bodies in tropical and subtropical regions of the world. *Chromobacterium violaceum* is one of the four Gram-Negative bacilli i.e.-VACS-Vibrio, Aeromonas, *Chromobacterium* and *Shewanella* which are catalase positive and possess Cytochrome C oxidase enzyme. These are differentiated on the basis of various biochemical tests.

Violacein is a secondary metabolite produced by *C. violaceum* whose production is regulated by quorum sensing mechanism, and hence this bacteria is of keen interest in the field of biotechnology and microbiology research laboratories.⁶ Violacein is well known for its varied biological activities, it has antibiotic action against many Gram-positive bacteria including *Staphylococcus aureus*.⁵ Violacein also behaves as an anticancer agent, which have been studied against multiple cancer cell lines which include Human Colorectal adenocarcinoma (SW480, DLD1)⁷, Human Choroidal melanoma (OCM-1),⁸ Human Uveal melanoma (92.1),⁸ among others. Violacein is also inhibitory to bacterial parasites.⁹

Cases have been reported worldwide⁵ with maximum cases from United States(>34), followed by Australia and India (>10 each)⁵ Well known in the field of biotechnology, it is rarely implicated in infectious diseases but can cause a varied spectrum of infections including urinary tract infection, skin and soft tissue infections, septicaemia, and solid organ abscess.^{8,10} Case reports reporting chronic

granulomatosis, osteomyelitis, cellulitis, periorbital and ocular infections have also been published.^{11–13}

C. violaceum septicaemia is highly fatal due to its ability to spread rapidly owing to the presence of one polar and one or two subpolar or lateral flagella¹¹ and secretion of an extracellular protein collagenase.¹⁴ Fatality as high as 65% has been reported.⁵ Nearly all cases of septicaemia are preceded by wound infection, as also seen in our case. *C. violaceum* can form abscesses in various organs like kidney, spleen, liver, etc. Hidden micro-abscess or septic foci may develop in a patient's internal organs which may lead to relapses. Therefore, it is necessary to treat patients with *C. violaceum* infection for an extended period and maintain close follow-up.⁵

Most of the strains (>90%) are pigment producers. No clarity exists on whether violacein is a major virulence determinant as non-pigmented strains display similar pathogenicity as the pigmented ones according to study by Kaufman S.C.¹⁵ Tiwari et al. reported a case of non-pigmented strain of *C. violaceum* causing neonatal septicaemia.⁴

Immunodeficiency has been implemented as a potential risk factor owing to *C. violaceum* infection in patients with impaired immunity due to conditions like uncontrolled diabetes mellitus, chronic granulomatous disease, severe glucose-6-phosphate dehydrogenase deficiency, neutrophil dysfunction, and systemic lupus erythematosus.^{16–18} All these conditions had been ruled out in our case reports.

C. violaceum is inherently resistant to penicillin and 1st and 2nd generation cephalosporins. Active antimicrobial agents include chloramphenicol, fluoroquinolones, aminoglycosides, carbapenems, piperacillin-tazobactam, tetracycline and trimethoprim-sulfamethoxazole.^{4,5,14}

As with previous studies, these current case outcomes reflect complete clinical examination with proper history of patient will help reveal uncommon etiology. Early intervention with administration of antimicrobial therapy is crucial to effectively manage severe life-threatening infections.

Microbiologist must make clinical rounds with the treating physicians and correlate microbiology lab reports with clinical condition and share his expertise in clinching the etiological agents of infectious disease.

6. Acknowledgements

None.

7. Conflicts of Interest

All contributing authors declare no conflicts of interest.

8. Source of Funding

None.

References

1. Woolley PG. 1905.
2. Sneath PHA, Singh RB, Whelan JPF, Edwards D. FATAL INFECTION BY CHROMOBACTERIUM VIOLACEUM. *The Lancet*. 1953;262(6780):276–277. Available from: [https://dx.doi.org/10.1016/s0140-6736\(53\)91132-5](https://dx.doi.org/10.1016/s0140-6736(53)91132-5). doi:10.1016/s0140-6736(53)91132-5.
3. Sharmin S, Jahan AA, Kamal SMM, Sarker P. Fatal Infection Caused by Chromobacterium violaceum: A Case Report from a Tertiary Care Hospital in Bangladesh. *Case Reports in Infectious Diseases*. 2019;2019:1–4. Available from: <https://dx.doi.org/10.1155/2019/6219295>. doi:10.1155/2019/6219295.
4. Tiwari S, Pattanaik S, Beriha S. Nonpigmented strain of Chromobacterium violaceum causing neonatal septicemia: A rare case report. *Indian Journal of Pathology and Microbiology*. 2017;60(3):427–427. Available from: https://dx.doi.org/10.4103/ijpm.ijpm_479_16. doi:10.4103/ijpm.ijpm_479_16.
5. Choi SY, hye Yoon K, Lee JJ, Mitchell RJ. Violacein: Properties and Production of a Versatile Bacterial Pigment. *BioMed Research International*. 2015;2015:1–8. Available from: <https://dx.doi.org/10.1155/2015/465056>. doi:10.1155/2015/465056.
6. McClean KH, Winson MK, Fish L, Taylor A, Chhabra SR, Camara M, et al. Quorum sensing and Chromobacterium violaceum: exploitation of violacein production and inhibition for the detection of N-acylhomoserine lactones. *Microbiology*. 1997;143(12):3703–3711. Available from: <https://dx.doi.org/10.1099/00221287-143-12-3703>. doi:10.1099/00221287-143-12-3703.
7. Kodach LL, Bos CL, Durán N, Peppelenbosch MP, Ferreira CV, Hardwick JCH. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. *Carcinogenesis*. 2006;27(3):508–516. Available from: <https://dx.doi.org/10.1093/carcin/bgi307>. doi:10.1093/carcin/bgi307.
8. Saraiva VS, Marshall JC, Cools-Lartigue J, Burnier MN. Cytotoxic effects of violacein in human uveal melanoma cell lines. *Melanoma Research*. 2004;14(5):421–424. Available from: <https://dx.doi.org/10.1097/00008390-200410000-00014>. doi:10.1097/00008390-200410000-00014.
9. Matz C, Webb JS, Schupp PJ, Phang SY, Penesyan A, Egan S, et al. Marine Biofilm Bacteria Evade Eukaryotic Predation by Targeted Chemical Defense. *PLoS ONE*. 2008;3(7):e2744–e2744. Available from: <https://dx.doi.org/10.1371/journal.pone.0002744>. doi:10.1371/journal.pone.0002744.
10. Chou YL, Yang PY, Huang CC, Leu HS, Tsao TC. Fatal and non-fatal chromobacterial septicemia: report of two cases. *Chang Gung Med J*. 2000;23(8):492–499.
11. Kumar MR, Chromobacterium. A rare bacterium isolated from a wound over the scalp. *Int J App Basic Med Res*. 2012;2(1):70–72.
12. Carter E, Cain K, Rutland B. Chromobacterium violaceum cellulitis and sepsis following cutaneous marine trauma. *Cutis*. 2008;81(3):269–72.
13. Feldman RB, Stern GA, Hood CI. Chromobacterium violaceum infection of the eye. A report of two cases. *Arch Ophthalmol*. 1984;102(5):711–714.
14. Thwe PM, Ortiz DA, Wankewicz AL, Hornak JP, Williams-Bouyer N, Ren P. The Brief Case: Recurrent Chromobacterium violaceum bloodstream infection in a glucose-6-phosphate dehydrogenase (G6PD)-deficient patient with a severe neutrophil defect. *J Clin Microbiol*. 2020;58:312–331.
15. Kaufman SC, Ceraso D, Schugurensky A. First case report from Argentina of fatal septicemia caused by Chromobacterium violaceum. *Journal of Clinical Microbiology*. 1986;23(5):956–958. Available from: <https://dx.doi.org/10.1128/jcm.23.5.956-958.1986>. doi:10.1128/jcm.23.5.956-958.1986.
16. Mamluk RJ, Mamiok V, Mills GC, Daeschner CW, Schmalstieg FC, Anderson DC. Glucose-6-phosphate dehydrogenase deficiency, neutrophil dysfunction and Chromobacterium violaceum sepsis. *The Journal of Pediatrics*. 1987;111(6):852–854. Available from: [https://dx.doi.org/10.1016/s0022-3476\(87\)80203-2](https://dx.doi.org/10.1016/s0022-3476(87)80203-2). doi:10.1016/s0022-3476(87)80203-2.
17. Meher-Homji Z, Mangalore RP, Johnson PDR, Chua KYL. Chromobacterium violaceum infection in chronic granulomatous disease: a case report and review of the literature. *JMM Case Reports*. 2019;4(1):5084–5084.
18. Khadanga S, Karuna T, Dugar D, Satapathy SP. Chromobacterium violaceum-induced sepsis and multiorgan dysfunction, resembling melioidosis in an elderly diabetic patient: A case report with review of literature. *Journal of Laboratory Physicians*. 2017;9(04):325–328. Available from: https://dx.doi.org/10.4103/jlp.jlp_21_17. doi:10.4103/jlp.jlp_21_17.

Author biography

Iqra Anjum, Post Graduate Student

Maimoona Mustafa, Professor and HOD

Mohammed Khaleel, Professor

Cite this article: Anjum I, Mustafa M, Khaleel M. Chromobacterium violaceum: A report of two cases of septicemia and wound infection. *IP Int J Med Microbiol Trop Dis* 2021;7(1):57-61.